A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

Sponsor
Blokhin's Russian Cancer Research Center
Study ID
NCT07281001
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. — DRUG
    T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. Intravenous infusion

Study Details

This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation

Key Dates

First listed
Dec 15, 2025
Start date
Dec 31, 2025
Status verified
Nov 2025
Primary completion
May 31, 2026
Completion
May 31, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Patients with unresectable or metastatic HER2+ BC who have received one or more cycles T-DXd

Primary Outcome Measure

PFS [ Time Frame: 6 weeks ]

Central Contacts

Find similar trials

Nationwide
Breast cancer trialsOncology trialsBreast oncology trialsWomen's health trials

Related Studies